Teladoc Health Expands AI Capabilities for Hospitals and Health Systems with Advanced Virtual Sitter Solution

New artificial intelligence (AI) capabilities help hospitals and health systems deliver safer and more efficient care

Teladoc Health’s AI-enabled Virtual Sitter Solution

Using advanced, pre-trained algorithms, motion detection and pose estimation, the expanded solution can visually detect patient movement that could lead to falls, enabling faster intervention by bedside staff.

PURCHASE, NY, Nov. 25, 2024 (GLOBE NEWSWIRE) — Teladoc Health (NYSE: TDOC), the global leader in virtual care, announced today the launch of new AI-enabled capabilities to enhance its Virtual Sitter solution to improve patient safety, address workforce challenges, and enhance care delivery for hospitals and health systems.

Every year, nearly 1 million hospitalized patients experience falls, with more than 30% resulting in lasting injuries. According to the CDC, falls result in approximately $50 billion of medical costs each year, and put additional strain on hospitals.

Teladoc Health’s Virtual Sitter solution helps address this critical issue. Leveraging AI, a single remote staff member can now monitor up to 25% more patients, helping to increase the capacity of healthcare inpatient teams. This latest innovation builds on Teladoc Health’s broader suite of inpatient connected care solutions, which support virtual nursing, physician consults, interpretive services, and other hybrid care services that help reduce the administrative burden on bedside staff and improve both clinician and patient satisfaction.

“For more than a decade, we’ve pioneered new ways for technology to support human interaction in patient care, helping hospitals and health systems transform care delivery and meet their most pressing challenges,” said Andy Puterbaugh, Teladoc Health President of Hospitals and Health Systems. “New applications of AI are now accelerating our impact, supporting continuous improvement of our fully integrated suite of connected care solutions, including Virtual Sitter.”

Using advanced, pre-trained algorithms, motion detection and pose estimation, the expanded solution can visually detect patient movement that could lead to falls, enabling faster intervention by bedside staff. Integrated within Teladoc Health’s TV Pro devices, the technology runs on the edge, using local processing power to improve the security of Protected Health Information (PHI) and system performance.

The AI-enabled Virtual Sitter solution is now commercially available and is already being implemented with select clients. To learn more about Teladoc Health’s expanded Virtual Sitter solution, click here. For more information about Teladoc Health’s integrated virtual care solutions for hospitals and health systems, click here.

About Teladoc Health

Teladoc Health empowers all people everywhere to live their healthiest lives by transforming the healthcare experience. As the world leader in whole-person virtual care, Teladoc Health uses proprietary health signals and personalized interactions to drive better health outcomes across the full continuum of care, at every stage in a person’s health journey. Teladoc Health leverages more than two decades of expertise and data-driven insights to meet the growing virtual care needs of consumers and healthcare professionals. For more information, please visit www.teladochealth.com.

Contact 
Lou Serio  
PR@teladochealth.com  
+1 202-569-9715

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/f2f56c05-a92a-4978-84d1-ffb7e2931f04

Staff

Recent Posts

The Power of Tracking: New Preliminary Data Underscores How MyFitnessPal Supports Weight Management Goals

Research highlights how nutrition tracking drives success for weight loss and health goals NEW YORK,…

3 hours ago

Vivos Inc.’s IsoPet® Division Achieves Exceptional Growth in 2024, Expanding Certified Veterinary Clinics Nationwide

Richland, WA, Dec. 26, 2024 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL) is pleased to…

6 hours ago

Assembly Biosciences Reports Interim Phase 1b Results from Clinical Trial Evaluating Next-Generation Capsid Assembly Modulator Candidate ABI-4334 in Chronic Hepatitis B

– ABI-4334 was well-tolerated with a favorable safety profile and half-life supporting once-daily oral dosing…

6 hours ago

Optinose Announces 1-for-15 Reverse Stock Split

YARDLEY, Pa., Dec. 26, 2024 (GLOBE NEWSWIRE) -- Optinose, Inc. (NASDAQ: OPTN), a pharmaceutical company…

6 hours ago